Skip to main content

Table 2 Early adverse events related a to treatment (≥10%) per patient (%) according to NCI-CTC criteria v3.0

From: A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features

  Arm A Arm B
(BVZ + CAP + RT) (CAP + RT)
(n° patients = 44) (n° patients = 46)
  % grade 1/2 % grade 3 % grade 1/2 % grade 3
Astenia/fatigue 55 2 24 -
Diarrhea 36 - 41 -
Dysuria 18 - 30 -
Rectal tenesmus 18 - 17 -
Nausea 13 - 11 -
Hand-foot syndrome 14 - 4 2
Anorectal discomfort 9 2 9 -
Anorexia 9 - 11 -
  1. Note: there were no grade 4 events.
  2. aAn adverse event was considered attributable to bevacizumab, capecitabine or radiation if it was deemed remotely, possibly or probably related.